公开(公告)号：US20140221448A1

公开(公告)日：2014-08-07

申请号：US14249658

申请日：2014-04-10

Applicant: E I DU PONT DE NEMOURS AND COMPANY

Inventor： Jeffrey Keith Long ,  Mary Ann Hanagan ,  Eric Allen Marshall ,  Amy X. Ding

IPC: A01N43/56

CPC classification number: A01N43/56 ,  C07D231/10 ,  C07D231/12 ,  C07D231/18 ,  C07D231/38 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04

Abstract: Disclosed are compounds of Formula 1 and Formula 1A including all stereoisomers, N-oxides, and salts thereof, wherein Q1, Q2, R1, R2, R4, R5 and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 or Formula 1A and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Abstract translation: 公开了式1和式1A的化合物，其包括所有立体异构体，N-氧化物及其盐，其中Q1，Q2，R1，R2，R4，R5和X如本公开所定义。 还公开了含有式1或式1A化合物的组合物和用于控制由真菌病原体引起的植物病害的方法，包括施用有效量的本发明化合物或组合物。

公开(公告)号：US20140206691A1

公开(公告)日：2014-07-24

申请号：US14226868

申请日：2014-03-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jagabandhu Das ,  Ramesh Padmanabha ,  Ping Chen ,  Derek Norris ,  Arthur M.P. Doweyko ,  Joel C. Barrish ,  John Wityak

IPC: C07D277/56 ,  C07D417/14 ,  C07D491/113 ,  C07D417/12 ,  C07D417/06

CPC classification number: C07D277/56 ,  C07C233/65 ,  C07C237/40 ,  C07D213/81 ,  C07D213/82 ,  C07D231/38 ,  C07D233/90 ,  C07D239/42 ,  C07D263/48 ,  C07D409/12 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D491/113

Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

Abstract translation: 新的环状化合物及其盐，含有这些化合物的药物组合物，以及使用这些化合物治疗蛋白质酪氨酸激酶相关疾病如免疫学和肿瘤学疾病的方法。

公开(公告)号：US08754115B2

公开(公告)日：2014-06-17

申请号：US13816847

申请日：2011-08-31

Applicant: Jeffrey Keith Long ,  Paula Louise Sharpe ,  Amy X Ding

Inventor： Jeffrey Keith Long ,  Paula Louise Sharpe ,  Amy X Ding

IPC: A61K31/415 ,  C07D231/10

CPC classification number: A01N43/56 ,  C07D231/10 ,  C07D231/12 ,  C07D231/18 ,  C07D231/38 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04

Abstract: Disclosed are compounds of Formula 1 and Formula 1A including all stereoisomers, N-oxides, and salts thereof, wherein Q1, Q2, R1, R2, R4, R5 and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 or Formula 1A and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Abstract translation: 公开了式1和式1A的化合物，其包括所有立体异构体，N-氧化物及其盐，其中Q1，Q2，R1，R2，R4，R5和X如本公开所定义。 还公开了含有式1或式1A化合物的组合物和用于控制由真菌病原体引起的植物病害的方法，包括施用有效量的本发明化合物或组合物。

公开(公告)号：US20140107125A1

公开(公告)日：2014-04-17

申请号：US13872819

申请日：2013-04-29

Applicant: Dermira (Canada), Inc.

Inventor： Zaihui Zhang ,  Timothy S. Daynard ,  Mikhail A. Chafeev ,  Shisen Wang ,  Gregory B. Chopiuk ,  Serguei V. Sviridov

IPC: C07D417/12 ,  C07D403/12 ,  C07D405/12 ,  C07D231/38

CPC classification number: C07D417/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/655 ,  C07D231/04 ,  C07D231/38 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04

Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

Abstract translation: 提供药物组合物和化合物。 本发明化合物表现出抗增殖活性，并可能促进缺乏细胞周期和死亡正常调节的细胞凋亡。 在本发明的一个实施方案中，提供了与生理上可接受的载体组合的化合物的药物组合物。 该药物组合物可用于治疗过度增殖性疾病，该疾病包括肿瘤生长，淋巴组织增生性疾病，血管生成。 本发明的化合物是取代的吡唑和吡唑啉。

公开(公告)号：US20140088105A1

公开(公告)日：2014-03-27

申请号：US14087773

申请日：2013-11-22

Applicant: David Beattie ,  Andrew James Culshaw ,  Lisa Rooney ,  Emily Stanley

Inventor： David Beattie ,  Andrew James Culshaw ,  Lisa Rooney ,  Emily Stanley

IPC: A61K31/5377 ,  A61K31/166 ,  A61K45/06 ,  C07D213/74 ,  A61K31/426 ,  A61K31/44 ,  C07D231/38 ,  A61K31/415 ,  C07D277/42 ,  C07C233/79 ,  A61K31/4406

CPC classification number: A61K31/5377 ,  A61K31/166 ,  A61K31/415 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4406 ,  A61K45/06 ,  C07C233/79 ,  C07C255/58 ,  C07C311/39 ,  C07C317/28 ,  C07C2601/14 ,  C07D209/08 ,  C07D213/74 ,  C07D213/82 ,  C07D213/84 ,  C07D215/38 ,  C07D231/12 ,  C07D231/16 ,  C07D231/38 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D239/42 ,  C07D249/12 ,  C07D249/14 ,  C07D257/04 ,  C07D257/06 ,  C07D261/14 ,  C07D277/04 ,  C07D277/42 ,  C07D295/135 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.

Abstract translation: 描述了可用作促肾上腺皮质激素释放因子（CRF1）受体拮抗剂的环己基酰胺衍生物。

公开(公告)号：US08673940B2

公开(公告)日：2014-03-18

申请号：US13557770

申请日：2012-07-25

Applicant: Wolfgang Froestl ,  Nampally Sreenivasachary ,  Sophie Lohmann ,  Maria Pilar Lopez Deber ,  Andreas Muhs ,  Maria Pihlgren Bosch

Inventor： Wolfgang Froestl ,  Nampally Sreenivasachary ,  Sophie Lohmann ,  Maria Pilar Lopez Deber ,  Andreas Muhs ,  Maria Pihlgren Bosch

IPC: A61K31/44

CPC classification number: C07D401/12 ,  C07D213/74 ,  C07D213/75 ,  C07D231/38 ,  C07D277/42 ,  C07D403/12 ,  C07D405/04 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to novel compounds of formula (II) that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating, or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

Abstract translation: 本发明涉及新的式（II）化合物，其可用于治疗与淀粉样蛋白（例如阿尔茨海默病）相关的一组疾病和异常以及与淀粉状蛋白样蛋白相关的疾病或病症。 本发明的化合物还可以用于治疗与视觉系统的组织中的病理学异常/变化相关的眼部疾病。 本发明还涉及包含这些化合物的药物组合物和这些化合物用于制备用于治疗或预防与淀粉样蛋白和/或淀粉样蛋白样蛋白相关的疾病或病症的药物的用途。 还公开了治疗或预防与淀粉样蛋白和/或淀粉样蛋白样蛋白相关的疾病或病症的方法。

公开(公告)号：US08623101B2

公开(公告)日：2014-01-07

申请号：US13930318

申请日：2013-06-28

Applicant: Fujifilm Corporation

Inventor： Keiichi Tateishi ,  Yoshihiko Fujie ,  Youichirou Takeshima

IPC: C09B67/22 ,  C09D11/00

CPC classification number: C09D11/322 ,  C07D231/38 ,  C07D417/12 ,  C07D417/14 ,  C09B35/03 ,  C09B35/34 ,  C09B67/0046 ,  C09B67/0055 ,  C09D11/328

Abstract: There is provided a coloring composition containing at least a first coloring material and at least a second coloring material, in which the first coloring material is a compound represented by the following Formula (Y), the second coloring material is, for example, the following compound 8, and the mass ratio of the content (% by mass) of the second coloring material in the composition to the content (% by mass) of the first coloring material in the composition is 0.001 to 1.0. Formula (Y) In Formula (Y), a plurality of M each independently represent a hydrogen atom or a cation, and when M represents a cation, M represents a Li+ ion, a Na+ ion, a K+ ion or a NH4+ ion.

Abstract translation: 提供了含有至少第一着色材料和至少第二着色材料的着色组合物，其中第一着色材料是由下式（Y）表示的化合物，第二着色材料是例如以下 化合物8，组合物中第二着色材料的含量（质量％）与组合物中第一着色材料的含量（质量％）的质量比为0.001〜1.0。 式（Y）在式（Y）中，多个M各自独立地表示氢原子或阳离子，M表示阳离子时，M表示Li +离子，Na +离子，K +离子或NH4 +离子。

公开(公告)号：US20130284064A1

公开(公告)日：2013-10-31

申请号：US13930318

申请日：2013-06-28

Applicant: FUJIFILM CORPORATION

Inventor： Keiichi TATEISHI ,  Yoshihiko FUJIE ,  Youichirou TAKESHIMA

IPC: C09D11/00

CPC classification number: C09D11/322 ,  C07D231/38 ,  C07D417/12 ,  C07D417/14 ,  C09B35/03 ,  C09B35/34 ,  C09B67/0046 ,  C09B67/0055 ,  C09D11/328

Abstract: There is provided a coloring composition containing at least a first coloring material and at least a second coloring material, in which the first coloring material is a compound represented by the following Formula (Y), the second coloring material is, for example, the following compound 8, and the mass ratio of the content (% by mass) of the second coloring material in the composition to the content (% by mass) of the first coloring material in the composition is 0.001 to 1.0. In Formula (Y), a plurality of M each independently represent a hydrogen atom or a cation, and when M represents a cation, M represents a Li+ ion, a Na+ ion, a K+ ion or a NH4+ ion.

Abstract translation: 提供了含有至少第一着色材料和至少第二着色材料的着色组合物，其中第一着色材料是由下式（Y）表示的化合物，第二着色材料是例如以下 化合物8，组合物中第二着色材料的含量（质量％）与组合物中第一着色材料的含量（质量％）的质量比为0.001〜1.0。 在式（Y）中，多个M各自独立地表示氢原子或阳离子，当M表示阳离子时，M表示Li +离子，Na +离子，K +离子或NH4 +离子。

公开(公告)号：US20130217891A1

公开(公告)日：2013-08-22

申请号：US13768519

申请日：2013-02-15

Applicant: The Procter & Gamble Company

Inventor： Wolfram GEIBEL ,  Ingo WEBER ,  Armin OSAN ,  Markus SPECKBACHER

IPC: C07D231/38

CPC classification number: C07D231/10 ,  C07D231/38

Abstract: A telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1H-pyrazole salt derivatives of formula (I), the compound (I) itself, and its use as an intermediate in the fabrication of 1-alkyl-4,5-diaminopyrazole salts of general formula (IX). The compounds of formula (IX) can be used as precursor dyes in oxidative hair dye compositions. R is a mono- or poly-substituted or unsubstituted, straight or branched, saturated or mono- or poly-unsaturated, alkyl group. HZ and HZ′ are organic or mineral acids.

Abstract translation: 式（I）的5-氨基-4-亚硝基-1-烷基-1H-吡唑盐衍生物，化合物（I）本身及其在制备1-烷基-4， 通式（Ⅸ）的5-二氨基吡唑盐。 式（Ⅸ）化合物可用作氧化染发组合物中的前体染料。 R是单或多取代或未取代的直链或支链饱和或单或多不饱和的烷基。 HZ和HZ'是有机或无机酸。

公开(公告)号：US08415346B2

公开(公告)日：2013-04-09

申请号：US13056180

申请日：2009-07-21

Applicant: Michael Altman ,  Kevin Wilson

Inventor： Michael Altman ,  Kevin Wilson

IPC: A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  C07D231/38 ,  C07D413/12 ,  C07D403/12 ,  C07D417/12

CPC classification number: C07D231/38 ,  C07D401/12

Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

Abstract translation: 本发明提供抑制四种已知的哺乳动物JAK激酶（JAK1，JAK2，JAK3和TYK2）的化合物。 本发明还提供了包含这种抑制化合物的组合物和通过将该化合物施用于需要治疗骨髓增生性疾病或癌症的患者的JAK1，JAK2，JAK3和TYK2的活性的方法。